INS and metabolic dysfunction-associated steatotic liver disease: Together, these studies indicate that the small molecules processing a reduction in liver inflammation and fibrosis as well as an improvement in insulin sensitivity and metabolic complications will be the pharmacological medication targets of anti-NAFLD drug discovery.